TGFB1 and non-small cell lung carcinoma: Clinical trials are under development to study triple-combinations of TGFβ inhibitors, RT and ICIs in non-small cell lung carcinoma (NSCLC), hepatocellular carcinoma and pancreatic tumours [95, 96].